BAFF and Graves' disease

Published: 30 June 2022| Version 1 | DOI: 10.17632/br2s5cfk66.1
Contributor:

Description

This a dataset summarizing data of BAFF level and polymorphisms investigation in Graves' disease patients

Steps to reproduce

Subjects The required sample size was calculated in two ways using an online calculator (https://statulator.com/SampleSize/ss2M.html) in order to achieve a power of 80% and a significance level of 5% as follow: 1) Calculation based on the difference in BAFF levels: The mean BAFF level in controls was 493.6 pg/ml with a standard deviation (SD) of 118.4 pg/ml. Assuming a true difference in means between GD patients and controls of 360 (3 SD in controls group) pg/ml, together with an expected SD in patients of 240 (2 SD in controls group) pg/ml, the study requires a sample size of 50 for each group. 2) Calculation based on the difference in BAFF alleles frequencies of 20% with a controls/patients’ ratio of 2: • rs9514827 SNP: given a C allele (minor) frequency in controls of 0.293, the required sample size is 57 for the patients’ group and 114 for the controls group. • rs1041569 SNP: given a T allele (minor) frequency in controls of 0.178, the required sample size is 56 for the patients’ group and 112 for the controls group. • rs9514828 SNP: given a T allele (minor) frequency in controls of 0.477, the required sample size is 61 for the patients’ group and 122 for the controls group. This study included 62 GD patients and 152 healthy voluntary blood donors from the same ethnic origin (Tunisian). The 62 GD patients were prospectively investigated in the endocrinology department of the Charles Nicolle Hospital in Tunis from June 2020 to September 2021. GD diagnosis was confirmed when the following criteria were met: 1) positive TRAB, 2) Low TSH level, 3) normal or high free thyroxine (fT4) level and 4) decreased echogenicity and enhanced blood flow in thyroid ultrasound or increased uptake in the iodine-123 thyroid scintigraphy. Controls were adult blood donors matched in age, gender and ethnicity with the GD patients. The ethnicity (Tunisian) of patients and controls was determined by oral survey. Methods Blood sampling Blood samples from all subjects were collected at the Immunology laboratory of the Charles Nicolle Hospital on EDTA and dry tubes before treatment, and at 6 and 12 months under treatment. Upon receipt, each tube was centrifuged at 3000 rpm for 15 minutes. The serum, aliquoted in 1 ml tubes and frozen at -80°C, was used for the measurement of serum BAFF. The cell pellet obtained from EDTA tubes was used for the extraction of genomic DNA by a standard salting-out procedure. Serum BAFF measurement Serum BAFF was measured by a quantitative sandwich ELISA according to the recommended protocol by the manufacturer (Quantikine® Human BAFF Immunoassay, R&D Systems, Minneapolis, MN, USA). Levels of s-BAFF are expressed in pg/ml. BAFF genotyping The Hardy-Weinberg equilibrium was verified for the three studied SNPs via internet (https://gene-calc.pl/hardy-weinberg-page). BAFF haplotypes, defined by the 3 SNPs, were analyzed using a freely available online software (https://www.snpstats.net/start.htm).

Institutions

Universite de Tunis El Manar

Categories

Patient with Chronic Illness